Business Wire (Fri, 14-Aug 4:55 PM ET)
Silence Therapeutics Announces Major ADS Public Offering
TipRanks (Wed, 12-Aug 5:48 PM ET)
Silence Therapeutics Prices $175 Million Upsized Offering to Advance siRNA Therapies
Market Chameleon (Wed, 12-Aug 4:46 AM ET)
Silence Therapeutics prices upsized $175M ADS offering at $13.50 each
Seeking Alpha News (Wed, 12-Aug 1:37 AM ET)
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
Business Wire (Tue, 11-Aug 11:20 PM ET)
Morgan Stanley maintains Overweight rating on Silence Therapeutics
Seeking Alpha News (Tue, 11-Aug 12:49 PM ET)
Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley
TipRanks (Tue, 11-Aug 7:55 AM ET)
TipRanks (Mon, 10-Aug 10:10 PM ET)
Silence Therapeutics launches $150M ADS offering
Seeking Alpha News (Mon, 10-Aug 4:14 PM ET)
Business Wire (Mon, 10-Aug 4:01 PM ET)
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics PLC - American Depository Share trades on the NASDAQ stock market under the symbol SLN.
As of August 14, 2026, SLN stock price declined to $13.72 with 754,092 million shares trading.
SLN has a beta of 1.04, meaning it tends to be more sensitive to market movements. SLN has a correlation of 0.02 to the broad based SPY ETF.
SLN has a market cap of $647.79 million. This is considered a Small Cap stock.
Last quarter Silence Therapeutics PLC - American Depository Share reported $0 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.06.
In the last 3 years, SLN traded as high as $27.72 and as low as $1.97.
The top ETF exchange traded funds that SLN belongs to (by Net Assets): IBB, GWX, APIE, IBBQ, BIB.
SLN has outperformed the market in the last year with a price return of +134.5% while the SPY ETF gained +21.6%. SLN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +96.6% and +18.1%, respectively, while the SPY returned +4.8% and +4.7%, respectively.
SLN support price is $13.15 and resistance is $14.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLN shares will trade within this expected range on the day.